AMZN
Amazon.com, Inc.
AMZN has the edge over XPOF overall, supported by lower modeled downside and stronger valuation.
XPOF
Xponential Fitness, Inc.
XPOF's outlook is improving, though it still trails on the overall score.
AMZN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Weak | |
| Healthy |
AMZN's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
XPOF Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Weak | |
| Weak |
XPOF's revenue is currently healthy, and its profitability is stable, but its cash flow and balance sheet are weak.
AMZN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 22x | $267 | — |
| Forward | 27x | $267 | — |
| Cheap | 34x | $415 | +55% |
| Fair | 60x | $745 | +179% |
| Expensive | 102x | $1,262 | +372% |
Historical ranges are pointers, not guarantees.
AMZN's PE is in its cheap range at 22x, but its recent earnings include one-off gains. On analysts' estimates for next year's earnings, today's price would be 27x.
XPOF PE Valuation
XPOF has no meaningful PE right now: it lost money over the past year.
AMZN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Growth | |
| Improving | |
| Moderate | |
| Moderate |
AMZN has the edge over XPOF on the outlook, with more favorable revenue expectations.
XPOF Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect XPOF's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
AMZN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.87 | -20% |
| Q3 2026 | $12.37 | +75% |
| Q2 2026 | $12.43 | +89% |
| Q1 2026 | $8.36 | +36% |
| Q4 2025 | $7.17 | +30% |
| Q3 2025 | $7.08 | +52% |
| Q2 2025 | $6.56 | +57% |
| Q1 2025 | $6.14 | +72% |
| Q4 2024 | $5.53 | +91% |
AMZN has the edge over XPOF on earnings quality, reporting a profit while its opponent remains loss making.
XPOF Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.49 | — |
| Q3 2026 | -$1.20 | +$0.48 |
| Q2 2026 | -$1.48 | +$0.31 |
| Q1 2026 | -$1.39 | +$0.68 |
| Q4 2025 | -$1.47 | +$0.80 |
| Q3 2025 | -$1.68 | -$0.53 |
XPOF is still losing money, but less than at its worst: $1.20 per share over the past year, against $2.27 at its worst in late 2024.
AMZN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $201.9B | +12% |
| Q2 2026 | $200.6B | +20% |
| Q1 2026 | $181.5B | +17% |
| Q4 2025 | $213.4B | +14% |
| Q3 2025 | $180.2B | +13% |
| Q2 2025 | $167.7B | +13% |
| Q1 2025 | $155.7B | +8.6% |
| Q4 2024 | $187.8B | +10% |
AMZN has the edge over XPOF on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | +4.2 points |
| Q2 2026 | 14% | +2.3 points |
| Q1 2026 | 13% | +1.3 points |
| Q4 2025 | 12% | +0.4 points |
| Q3 2025 | 9.7% | -1.3 points |
| Q2 2025 | 11% | +1.5 points |
| Q1 2025 | 12% | +1.1 points |
| Q4 2024 | 11% | +3.5 points |
AMZN's operating margin was 14% last quarter, up 4.2 points from the same quarter a year ago, near the top of its range since 2019.
XPOF Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.9M | +23% |
| Q2 2026 | $2.7M | -1% |
| Q1 2026 | $2.2M | -17% |
| Q4 2025 | $3.4M | -7.3% |
| Q3 2025 | $2.4M | -37% |
| Q2 2025 | $2.7M | -22% |
| Q1 2025 | $2.6M | -14% |
| Q4 2024 | $3.6M | +18% |
XPOF's revenue is recovering but still below its 2022 peak: $3M last quarter, up 23% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 664% | +514 points |
| Q2 2026 | 352% | -191 points |
| Q1 2026 | 603% | +233 points |
| Q4 2025 | -245% | +1194 points |
| Q3 2025 | 150% | +318 points |
| Q2 2025 | 543% | +612 points |
| Q1 2025 | 370% | +128 points |
| Q4 2024 | -1439% | -1535 points |
XPOF has the edge over AMZN on profitability, with a higher operating margin.
AMZN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$34.8B | -8202% |
| Q2 2026 | -$8.8B | -2757% |
| Q1 2026 | -$18.2B | -$10.2B |
| Q4 2025 | $14.9B | -16% |
| Q3 2025 | $430M | -87% |
| Q2 2025 | $332M | -96% |
| Q1 2025 | -$8B | -297% |
| Q4 2024 | $17.8B | -36% |
AMZN's free cash flow was −$46.9B over the past year, against $10.6B the year before.
XPOF Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.1M | -50% |
| Q2 2026 | -$4.3M | -533% |
| Q1 2026 | -$22.2M | -514% |
| Q4 2025 | $10.2M | +1077% |
| Q3 2025 | $8.2M | +143% |
| Q2 2025 | $996K | +14% |
| Q1 2025 | $5.4M | +191% |
| Q4 2024 | $864K | +$4.9M |
XPOF has the edge over AMZN on cash flow, with more consistent year-over-year improvement.
AMZN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 0.3x | Very low |
| Q1 2026 | 0.1x | Very low |
| Q4 2025 | -0.1x | Net Cash |
| Q3 2025 | -0.1x | Net Cash |
| Q2 2025 | -0.0x | Net Cash |
| Q1 2025 | -0.1x | Net Cash |
| Q4 2024 | -0.2x | Net Cash |
AMZN has the edge over XPOF on leverage, with a lower net debt burden relative to earnings.
XPOF Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 11.5x | High |
| Q2 2026 | 17.1x | High |
| Q1 2026 | 14.0x | High |
| Q4 2025 | 14.4x | High |
| Q3 2024 | 16.4x | High |
| Q2 2024 | 9.1x | High |
| Q1 2024 | 4.2x | High |
| Q4 2023 | 5.1x | High |
XPOF's net debt is about 11 years of its operating earnings (EBITDA), down from 16 years a year ago.
AMZN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.1 | Neutral |
| Stochastic | 50.0 | Neutral |
AMZN's weekly RSI is 57 (neutral) and its Stochastic is 50 (neutral).
XPOF Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.2 | Neutral |
| Stochastic | 35.7 | Neutral |
XPOF's weekly RSI is 44 (neutral) and its Stochastic is 36 (neutral).
AMZN PE vs Consumer Cyclical Sector
| Metric | AMZN | Sector median | Relative |
|---|---|---|---|
| PE | 22x | 18x | 20% above |
| PE % | 4 | 47 | 43 pts below |
AMZN is trading at 22x earnings, a 20% premium to the Consumer Cyclical sector's median of 18x, though its recent earnings include one-off gains.
XPOF PE vs Consumer Cyclical Sector
XPOF has no meaningful PE right now: it lost money over the past year.
AMZN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $253.6 | 5.5% above |
| 20 week MA | $254.9 | 4.9% above |
| 50 week MA | $242.5 | 10% above |
| 100 week MA | $229.6 | 17% above |
| 200 week MA | $191.4 | 40% above |
AMZN has the edge over XPOF on trend strength, trading above more of its moving averages.
XPOF Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.50 | 2.9% above |
| 20 week MA | $5.11 | 9.4% below |
| 50 week MA | $6.17 | 25% below |
| 100 week MA | $8.00 | 42% below |
| 200 week MA | $12.8 | 64% below |
XPOF has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 64% below its 200-week average.
AMZN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $93.5 | $158.6 | +70% |
| 2021 | $158.6 | $171.1 | +7.8% |
| 2022 | $171.1 | $85.3 | -50% |
| 2023 | $85.3 | $151.9 | +78% |
| 2024 | $151.9 | $223.8 | +47% |
| 2025 | $223.8 | $232.5 | +3.9% |
| 2026 YTD | $232.5 | $267.4 | +15% |
AMZN has the edge over XPOF on returns for 2026, with the stronger performance.
XPOF Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $12.3 | $20.6 | +68% |
| 2022 | $20.6 | $22.9 | +11% |
| 2023 | $22.9 | $12.9 | -44% |
| 2024 | $12.9 | $12.8 | -0.4% |
| 2025 | $12.8 | $8.74 | -32% |
| 2026 YTD | $8.74 | $4.63 | -47% |
XPOF has finished three years in a row lower, and it's down 47% so far in 2026.